Abstract:Background: A subset of patients with rectal cancer who undergo neoadjuvant chemoradiation therapy will develop a complete pathologic tumor response. Complete nodal response is not universal in these patients and is difficult to assess clinically. Quantifying the risk of nodal disease would allow for targeted therapy with either radical resection or "watchful waiting." Objective: This study aimed to identify risk factors for residual nodal disease in ypT0 rectal adenocarcinoma. Design: This is a retrospective case control study. Settings: The National Cancer Database 2006 to 2014 was used to identify patients for this study. Patients: Patients with stage II/III rectal adenocarcinoma who completed chemoradiation therapy followed by resection and who had ypT0 tumors were included. Patients with metastatic disease and <2 lymph nodes evaluated were excluded. Patients were divided into 2 groups: node positive and node negative. Main outcome measures: The main outcome was nodal disease. The secondary outcome was overall survival. Results: A total of 42,257 patients with stage II/III rectal cancer underwent chemoradiation therapy and radical resection; 4170 (9.9%) patients had ypT0 tumors and 395 (9.5%) were node positive. Of patients with clinically node-negative disease (ie, pretreatment imaging), 6.2% were node positive after chemoradiation therapy and resection. In multivariable analysis, factors predictive of nodal disease included increasing (pretreatment) clinical N-stage, high tumor grade (3/4), perineural invasion, and lymphovascular invasion. Higher clinical T-stage was inversely associated with residual nodal disease. Overall 5-year survival was significantly different between patients with ypN0, ypN1, and ypN2 disease (87.4%, 82.2%, and 62.5%, p = 0.002). Limitations: This study was limited by the lack of clinical detail in the database and the inability to assess recurrence. Conclusions: Ten percent of patients with ypT0 tumors had positive nodes after chemoradiation therapy and resection. Factors associated with residual nodal disease included clinical nodal disease at diagnosis and poor histologic features. Patients with any of these features should consider radical resection regardless of tumor response. Others could be suitable for "watchful waiting" strategies. See Video Abstract at http://links.lww.com/DCR/A458.

T3N0 Rectal Cancer

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Nonoperative Management for Rectal Cancer

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

The current multidisciplinary management of rectal cancer

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Deciphering the Dilemma: Choosing the Optimal Total Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

Latest evidence on the management of early‐stage and locally advanced rectal cancer: a narrative review

Executive Summary of the American Radium Society on Appropriate Use Criteria for Nonoperative Management of Rectal Adenocarcinoma: Systematic Review and Guidelines

Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters

Locally Advanced Rectal Cancer: Time for Precision Therapeutics.

T1 colorectal cancer management in the era of minimally invasive endoscopic resection

How to Select the Most Suitable?

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

[Radiotherapy Standard and Progress in Locally Advanced Rectal Cancer].

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024

Point/Counterpoint #2

Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Evolving Standards of Care in the Management of Localized Colorectal Cancer

Re-evaluation of controversial issues in the treatment of cT3N0-2 rectal cancer: a 10-year cohort analysis using propensity-score matching

Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer